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Abstract
Background: Breast cancer (BC) is the most common cancer for women in the western world. From very few
cases an extraordinary increase in BC was observed in the Inuit population of Greenland and Canada although still
lower than in western populations. Previous data suggest that exposure to persistent organic pollutants (POPs)
might contribute to the risk of BC. Rat studies showed that perfluorinated compounds (PFCs) cause significantly
increase in mammary fibroadenomas. This study aimed at evaluating the association between serum levels of
POPs/PFCs in Greenlandic Inuit BC cases and their controls, and whether the combined POP related effect on
nuclear hormone receptors affect BC risk.
Methods: Thirty-one BC cases and 115 controls were sampled during 2000-2003 from various Greenlandic districts.
The serum levels of POPs, PFCs, some metals and the combined serum POP related effect on estrogen- (ER),
androgen- (AR) and Ah-receptor (AhR) transactivity were determined. Independent student t-test was used to
compare the differences and the odds ratios were estimated by unconditional logistic regression models.
Results: We observed for the very first time a significant association between serum PFC levels and the risk of BC.
The BC cases also showed a significantly higher concentration of polychlorinated biphenyls at the highest quartile.
Also for the combined serum POP induced agonistic AR transactivity significant association to BC risk was found,
and cases elicited a higher frequency of samples with significant POP related hormone-like agonistic ER
transactivity. The AhR toxic equivalent was lowest in cases.
Conclusions: The level of serum POPs, particularly PFCs, might be risk factors in the development of BC in Inuit.
Hormone disruption by the combined serum POP related xenoestrogenic and xenoandrogenic activities may
contribute to the risk of developing breast cancer in Inuit. Further investigations are needed to document these
study conclusions.
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Background
Breast cancer (BC) is the most common cancer for
women in the western world and the incidence has been
increasing since 1940. The highest incidence rates are
observed in North America, and the lowest risk is found
in Asia and Africa [1]. Breast cancer is also the most
common cancer in females in Europe with the highest
incidence in The Netherlands and Denmark and lowest
in the eastern part of Europe [2]. From very few cases in
the 1970’s an extraordinary increase in BC has been
observed in the Inuit population of Greenland and
Canada today [3,4]. Known established breast cancer
risk factors include genetic inheritance e.g. mutations in
the BRCA-1 and BRCA-2 genes [5], lifelong exposure to
estrogens (early menarche and late menopause increases
the risk), obesity after menopause, alcohol, smoking and
high intake of fat [2,6,7]. Some factors seem to reduce
the risk such as low age at first birth, large number of
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[6,7]. Thus, BC risk is influenced by genetics and repro-
ductive history, but the known risk factors only explain
less than a third of all cases and more than 70% of
women diagnosed with BC have no inherited or spora-
dic cancer. The risk of BC is thought to be modified by
lifestyle and environmental exposures. Results from
many studies have confirmed that BC is not a single dis-
ease with variable morphologic features and biomarkers,
but rather a group of molecularly distinct neoplastic dis-
orders [8].
The susceptibility to BC upon environmental expo-
sures might not only be as child, in puberty or young
but can be pre-determined in utero through alterations
of the hormonal environment caused by either maternal
diet and/or exposure to environmental chemicals with
endocrine activities that can modify the epigenome.
T h e s ee p i g e n e t i cm o d i f i c a t ions, inherited by somatic
daughter cells, lead to changes in mammary gland devel-
opment and increase the vulnerability for malignant
transformation [9]. An array of legacy persistent organic
pollutants (POPs) including polychlorinated dibenzo-
dioxins and polychlorinated dibenzofurans (PCDD/
PCDF), polychlorinated biphenyls (PCBs), and organo-
chlorine pesticides (OCPs) are potential endocrine dis-
rupters and can play an important role in the risk of
BC. These persistent and lipophilic compounds do bio-
magnify through the food web and bioaccumulate age
dependently in human and animals. PCBs have been
associated with effects being relevant for development of
BC such as estrogenic, tumour promoting, and immuno-
suppressive activities [10]. Evidence regarding organo-
chlorine exposure and BC risk is controversial. A case-
control study of Danish women showed a significant
doses relation between the risk of BC and the serum
level of the pesticide dieldrin, and a non-significant rela-
tion of BC risk at the highest level of dieldrin and PCBs
among BC women with a tumour with mutant p53
[11,12]. In contrast, Raaschou et al. 2005 found no asso-
ciation between persistent organochlorines (14 pesticides
and 18 PCBs) levels in adipose tissues and breast cancer
in postmenopausal Danish women [13]. Thus, no strong
evidence for the role of organochlorines, including
PCBs, in BC development was found. However, two stu-
dies found a 3-fold risk in postmenopausal breast cancer
with a A2455G mutation in the P450 polymorphic
CYP1A1 gene and high PCB levels compared with wild-
type alleles and low PCBs [14]. These associations
between PCB exposure and BC risk among genetically
susceptible and racially subgroups warrant further
studies.
Perfluorinated compounds (PFCs) are a large group of
chemicals used since the 1950’s in different industrial
and commercial applications (e.g. Teflon, carpets,
furniture, food stuff packing etc.). For a long time, these
fluorinated chemicals were considered metabolically
inert and nontoxic [15] and the carbon-fluorine bond
renders theses chemicals very resistant to biodegradation
and therefore persistent in the environment [15]. Avail-
able evidence suggest the transformation or biodegrada-
tion of precursor perfluorinated chemicals occurs by
both abiotic and biotic degradation pathways where per-
fluorooctane sulfonate (PFOS) and perfluorooctanoic
acid (PFOA) are typical final degradation products
[16,17]. In 2001, it was discovered that the PFCs were
accumulating in the environment and human tissues
with a global distribution [16-18]. Unlike the legacy
POPs (e.g. PCBs, OCPs) - which accumulate in lipid
rich tissues - PFCs bind to blood proteins and accumu-
late mainly in liver, kidney and bile secrets [19].
Humans are exposed to PFCs through occupational set-
tings, environmental exposures and/or through contact
with consumer goods (diet, air, water, food and house-
hold dust) where PFCs have been found.
The perfluoroalkyl acids (PFAAs) include the perfluor-
ocarboxylated acids (PFCAs) and perfluorosulfonated
acids (PFSAs), and the PFAAs include the two most stu-
died PFCs: PFOS and PFOA. These two compounds are
the most studied because existing laboratory procedures
in the past did not allow analyses of other PFCs that in
general exist in lower concentrations. PFOA and PFOS
are persistent in the environment and found in human
blood, breast milk and liver with half lives of 4 to 10
years [20]. The PFCs are found globally and governmen-
tal regulations in USA and Europe on use and produc-
tion of specific compounds such as PFOS and PFOA
have been made. Recently, PFOS has been added to
Annex B of the Stockholm Convention on POPs [21].
Biomonitoring studies have been carried out in almost
all part of the world in order to assess PFAAs levels and
temporal trends in the general population [22,23]. Eur-
opean studies observed serum and plasma concentra-
tions range from 1 to 116 ng/ml for PFOS and from 0.5
to 40 ng/ml for PFOA. The average plasma levels of
PFOS and PFOA in Danish pregnant women was 35.3
and 5.6 ng/ml, respectively, similar to most levels
reported for western country populations during the
same decade [24]. For middle aged women in Norway
slightly lower levels were reported (medians: PFOS; 20
ng/ml; PFOA; 4.4 ng/ml). Mean and median concentra-
tions from North American populations appear to be
slightly higher than European, Asian and Australian
p o p u l a t i o n s[ 2 2 ] .R e c e n t l yw ep e r f o r m e das u r v e yo f
serum PFCs in Greenlandic Inuit [25] showing similar
PFOS levels in Inuit women as found for Danish and
European women but lower PFOA levels.
The maternal level of PFOA or PFOS was found asso-
ciated with various reproductive and child health
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fecundity [27].
The biological effects of PFCs have been studied in
more detail mainly in rodents; little data are available
for other species and humans [19,30]. Studies in animals
have documented an array of toxicological outcomes
including liver hypertrophy and tumours [31], thyroid
hormone alterations, decreased serum cholesterol and
glucose, developmental toxicity, immunotoxicity, and
carcinogenic potency [32,33]. Animal and in vitro stu-
dies have also suggested that PFAAs may have potential
geno- and neurotoxic effects [34-36]. U.S. EPA has pro-
posed PFOA to be deemed as a rodent carcinogen with
relevance to humans [37].
A 2-year study in rats [38] reported a statistically sig-
nificant increase in mammary fibroadenomas and Leydig
cell adenomas suggesting impact of PFOA on reproduc-
tive tissues. Because of these data the U.S. EPA Science
Advisory Board recommended to reconsider the possible
impact of PFOA on mammary tissues. In 2007 White
and coworkers reported [39] that gestational exposure
to PFOA in mice compared to non exposed controls
was associated with altered mammary gland develop-
ment in dams and female offspring. A significant reduc-
tion in mammary differentiation among exposed dams
was evident, and also affected the epithelial involution
and altered milk protein gene expression [39,40].
Recently, estrogen-like properties of PFCs were
reported in human MCF-7 breast cancer cells suggesting
endocrine potentials [41].
The objective of this BC case-control epidemiologic
study in Greenlandic Inuit women was to evaluate the
serum level of legacy POPs and PFCs, blood metals, and
the combined xenobiotic serum POP related effect on
the functions of the estrogen- (ER) and androgen recep-
tors (AR) and the aryl hydrocarbon receptor (AhR)
functions.
Methods
Study population and Data collection
The subjects of breast cancer cases were taken from
Inuit women at the “Dronning Ingrids Hospital” in
Nuuk, where all breast cancer cases in Greenland are
registered. Approximately 80% of all BC cases were
included in the sampling period 2000-2003. Subjects of
controls were selected by frequency matching age and
districts from a cross sectional study of POP concentra-
tions and bone ultrasound measurement [42] and the
Arctic Monitoring and Assessment Programme (AMAP)
s t u d y[ 4 3 ] .T h ec o n t r o l sw e r em a t c h e dw i t ht h ec a s e s
having similar frequency of age ≤ 50, 51-55, 56-59, ≥
60yrs (see table 1) and then frequency matched with the
cases of the districts (see table of Figure 1). All subjects,
31 cases and 115 controls, were of Greenland Inuit
decent, defined as having more than two grandparents
born in Greenland. The sampling period was 2000-2003
with subjects from Nuuk, Upernavik, Qeqertarsuaq,
Narsaq, Tasiilaq, Qaqortoq, Sisimiut, Assiaat, and
Nanortalik. Figure 1 shows a map of Greenland, with
the collection sites.
All subjects completed the validated Danish standard
questionnaire. It included questions about demographic
and lifestyle parameters and allowed to document the
following risk factors for breast cancer: age, breastfeed-
ing, Body Mass Index (BMI), smoking, menopause
status.
Blood sample collection and analyses
Blood samples were taken when the breast cancer was
diagnosed and for controls when enrolled in the study
following the standard procedure and stored at -80°C
until analyses.
Concerning the chemical analyses and bio-activity
measurements both cases and controls were batch
together in the run of assays and the persons running
the assays were blinded to the samples of cases and
controls
Plasma legacy POPs and plasma lipid
T h el i p o p h i l i cp l a s m al e g a c yP O P sa n dl i p i d sw e r ea n a -
lysed at the Centre de Toxicologie of the Institut
N a t i o n a ld eS a n t eP u b l i q u ed uQ u e b e c( Q u e b e c ,
Canada) (CTQ), a certificated laboratory by Canadian
Association for Environmental Analytical Laboratories.
Plasma was extracted by 1:1:3 mixture of ammonium
sulphate: ethanol: hexane and then concentrated and
purified on two florosil columns. Twelve PCB congeners
[International Union for Pure and Applied Chemistry
(IUPAC) no. 99, 101, 105, 118, 128, 138, 153, 156, 170,
180, 183, 187], and eight OCPs [p,p’-DDT(dichlorodi-
phenyltrichloroethane) and its major metabolite p,p’-
DDE (p,p’-dichlorodiphenyl-dichloroethylene), b-hexa-
chlorocyclohexane (b-HCH), aldrin, hexachlorobenze
(HCB), oxychlorodane, cis-nonachlor and trans-nona-
chlor] were analysed in purified extracts by high-resolu-
tion gas chromatography with electron capture
detection. The detection limit was 0.08 μg/L for p, p’-
D D E ,p ,p ’-DDT and b-HCH, and 0.04 μg/L for other
pesticides and PCBs [42]. The measured PCBs and
OCPs were grouped as sum PCB and sum OCPs.
Plasma lipids were measured at CTQ using standard
enzymatic procedure. The total plasma lipid concentra-
tion was obtained from cholesterol esters, free choles-
terol, triglycerides and phospholipids as described
previously [44]. To obtain the lipid adjusted POPs data
(μg/kg lipid), the measured PCBs and pesticides (μg/L)
were divided by total plasma lipid (g/L) and multiplied
by 1000.
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S e r u mP F C sw e r em e a s u r e da tt h eN a t i o n a lE n v i r o n -
mental Research Institute, Aarhus University, Denmark.
Perfluoroheptanoic acid (PFHpA), perfluorooctanoic
acid (PFOA), perfluorononanoic acid (PFNA), perfluoro-
decanoic acid (PFDA), perfluoroundecanoic acid
(PFUnA), perfluorododecanoic acid (PFDoA), perfluoro-
tridecanoic acid (PFTrA), perfluorohexane sulfonate
(PFHxS), perfluorooctane sulfonate (PFOS) and per-
fluorooctane sulfonamide (PFOSA) were measured in
serum extracts. The extraction method was based on
ion pairing as described previously [45]. Instrumental
analysis was performed by liquid chromatography-tan-
dem mass spectrometry (LC-MS-MS) with electrospray
ionization (ESI). The analytes were separated on a C18
Betasil column (2.1 × 50 mm, Thermo Hypesil-Key-
stone, Bellafonte, PA, USA) using an Agilent 1100 Series
HPLC (Agilent Technologies, Palo Alto, CA). The
HPLC was interfaced to a triple quadruple API 2000
(Sciex, Concorde, Ontario, Canada) equipped with a
TurboIon Spray™ source operating in negative ion
mode. Detection of the analytes was based on retention
time and the most abundant mass transition corre-
sponding to an authentic standard. Confirmation of ana-
lyte identity was based on ther e l a t i v er e s p o n s eo ft h e
secondary mass transition to the primary mass transi-
tion. Quantification of the analytes was done using
response factors calculated from a four point calibration
curve consisting of blank samples (rabbit serum) spiked
with the analytes in the concentration range 1-50 ng/ml
and extracted following the same procedure as samples.
The samples were extracted and analyzed in batches
together with a procedural blank. The target compounds
were not detected in any of the blank samples. The
detection limit of the analytical method (MDL) was
defined as those concentrations of the analytes needed
Table 1 Demographic, lifestyle and reproductive characteristics of breast cancer patients and controls
Parameters Cases Controls p value
N (n) median 95% CI Min-max N (n) median 95% CI Min-max
Demographic and lifestyle factors
Age (years) 31 (31) 50 46.1; 56.7 29.0-80.0 115 (115) 54 49.1; 53.5 18-66 0.34
≤ 50 17 (54.8%) 37 (32.2%)
51-55 3 (9.70%) 26 (22.6%)
56-59 3 (9.70%) 17 (14.8%)
≥ 60 8 (25.8%) 35 (30.4%)
BMI (kg/m
2) 31 (13) 26.9 24.0; 29.1 16.5-34.4 115 (115) 26.4 26.4;27.2 16.6-43.4 0.69
<25 4 23.5 16.0; 22.3 16.5-25.0 42 23.0 21.7;23.0 16.1-25.0 0.84
25-29 8 27.6 26.6; 28.9 25.8-29.6 42 27.6 26.9;27.8 25.1-19.9 0.46
> 30 1 34.4 - - 31 33.2 33.1; 35.9 30.3-43.4 -
n-3/n-6 31 (29) 0.5 0.4; 0.6 0.2-1.7 115 (115) 0.5 0.5; 0.7 0.1-2.2 0.31
Serum cotinine (ng/ml) 31 (28) 11.6 33.3; 140.0 0-600.0 115 (96) 120 121.0; 188.0 0.0-799.0 0.052
Smoking status 31 (26) 115 (115) 0.77
Never 5 (19.2%) 21 (18.3%)
Former 3(11.5%) 20 (17.4%)
Current 18 (69.2%) 74 (64.3%)
Reproductive factors
Total number of full term pregnancies 31(16) 2.0 1.7; 2.8 1-4 115 (89) 3.0 3.2; 4.1 0.0-11.0 <0.0001
Ever breastfed 31(17) 115 (85)
Yes (%) 15 (88.2%) 76 (89.4%) 0.89
Menopausal status 31 (20) 115 (89)
Premenopausal (%) 11 (55.0%) 16 (18.0%) 0.001
Postmenopausal (%) 9 (45.0%) 73 (82.0%) 0.001
Serum E2 (nmol/l) 31(24)* 0.09 0.09; 0.23 0.03-0.51 115(59) 0.07 0.05; 0.16 0.01-1.59 0.10
Premenopausal 8 0.24 0.12; 0.38 0.06-0.44 11 0.13 0.05; 0.55 0.03-1.59
Postmenopausal 8 0.07 0.01; 0.25 0.03-0.51 48 0.07 0.06; 0.08 0.01-0.17
N: total number of subjects, n: number of subjects having information for the corresponding parameters.
BMI: body mass index
*: 24 cases had E2 data but for 8 no menopause status information was given.
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limits ranged from 0.1 to 0.4 ng/ml. Method perfor-
mance is currently tested by participating in the AMAP
Ring Test for Organic Pollutants in Human Serum orga-
nized by Institute Nationale de santé publique du Qué-
bec [46]. Satisfactory Z-scores were obtained by our
laboratory in the tests for PFCs.
The analysed PFCs were grouped into sumPFSA (sum of
PFOS, PFHxS and PFOSA) and sumPFCA (sum of PFHpA,
PFOA, PFNA, PFDA, PFUnA, PFDoA and PFTrA).
Blood metals
Whole blood metals including selenium (Se), zinc (Zn)
and the heavy metals lead (Pb), mercury (Hg) and
cadmium (Cd) were measured using Inductively
Coupled Plasma Mass Spectrometry (ICP-MS) after
digesting blood with nitric acid in the microwave at the
National Environmental Research Institute, Aarhus Uni-
versity, Denmark.
Plasma fatty acids
Plasma fatty acids were determined by capillary gas-
liquid chromatography at the Biology Department, Uni-
versity of Guelph, Canada [47]. The fatty acids composi-
tion of plasma phospholipids was expressed as a
percentage of the total area of all fatty acid peaks from
14:0 to 24:0. Plasma phospholipids of fatty acids corre-
spond to relative percentages of total fatty acids by
Figure 1 Geographical distribution of the breast cancer cases and controls.
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Page 5 of 16weight. The n-3 polyunsaturated fatty acids were
reported on the sum of C18:3, n-3; C18:4, n-3; C20:3, n-
3; C20:4, n-3; C20:5, n-3; C22:5, n-3; C22:6, n-3, and the
n-6 fatty acid acids was the sum of C18:2, n-6; C18:3, n-
6; C20:2, n-6; C20:3, n-6; C20:4, n-6; C22:2, n-6; C22:4,
n-6 and C22:5, n-6. The ratio between n-3 and n-6 is
known to be a strong indicator of marine food intake
and thus a good indicator of the relative consumption
of traditional versus imported food [48,49].
Serum cotinine determination
Cotinine is a metabolite of nicotine. The level of coti-
nine in the blood is proportionate to the amount of
exposure to tobacco smoke and thus it is a valuable
indicator of tobacco smoke exposure. The Calbiotech
Cotinine Direct ELISA Kit was used to measure the
serum cotinine (Calbiotech Inc., CA, USA) at Centre of
Arctic Environmental Medicine & Cellular & Molecular
Toxicology,, Department of Public Health, Aarhus Uni-
versity, Denmark. This assay is a solid phase competitive
ELISA and the absorbance was read on ELISA Reader at
450 nm. The serum cotinine concentration was
expressed as ng/ml and the limit detection was 1 ng/ml.
Measurement of serum estradiol
Solid phase fluoronimmunoassay was employed to
determine serum 17 b-Estradiol using DELFIA
® Estra-
diol kit (PerkinElmer Life and Analytical Sciences, Wal-
lac Oy, Turku, Finland) at Centre of Arctic
Environmental Medicine & Cellular & Molecular Toxi-
cology, Department of Public Health, University of Aar-
hus, Denmark. The principle of this assay is based on
competition between europium-labelled estradiol and
sample estradiol for polyclonal anti-estradiol antibodies.
The fluorescence of the samples were measured on a
fluorometer (Wallac 1420 Multilabel Counter, Perkin
Elmer life science, FIN) with protocol “56 E2” for auto-
matic measurement and result calculation. The serum
E2 concentration was expressed as nmol/L. The sensitiv-
ity of the assay was 0.05 nmol/L, and the intra- and
inter-assay coefficient of variation were less than 10%.
Serum POP related xenobiotic induced receptor
transactivities
SPE-HPLC fractionation of the serum samples for deter-
mination of ER and AR transactivity.
For determination of the combined serum POP related
xenoestrogen (XER) and xenoandrogen (XAR) receptor
transactivity a Solid Phase Extraction (SPE) and a High-
Performance Liquid Chromatography (HPLC) fractiona-
tion was performed on 3.6 ml serum to obtain the
serum fraction (F1) containing the actual mixture of
bio-accumulated lipophilic POPs separated from endo-
genous hormones. The SPE-HPLC F1 extracts were
analyzed for the actual combined xenohormone activity
in the ER and AR transactivation assays [50-52].
Measurement of XER-transactivity and XAR-transactivity
Determination of the ER transactivation was carried out
in the stable transfected MVLN cells, carrying the ERE-
luciferase reporter vector (kindly provided by M. Pons,
France) [51,53].
The AR transactivation was determined in the Chinese
Hamster Ovary cells (CHO-K1) by transient co-transfec-
tion with the MMTV-LUC reporter vector (kindly pro-
vided by Dr. Ronald M. Evans, Howard Huges Medical
institute, CA) and the AR expression plasmid pSVAR0
(kindly provided by Dr. A.O. Brinkmann, Erasmus Uni-
versity, Rotterdam) [52]. The luciferase activity was mea-
sured in a LUMIstar luminometer (BMG Lumistar,
RAMCON, Denmark) and corrected for cell protein by
fluorometric measurements in the WALLAC VICTOR2
(PerkinElmer, USA) at 355/460 nm wavelength as
described [53-55].
In each assay all samples were tested in triplicate in
two sets of tests: 1) the effect of the serum F1 POP
extract only (termed XER/XAR) to test primarily for
agonistic effect. The response of the serum F1 POP
extract was compared to the reference solvent control of
the analyses. When the F1 POP extract was significantly
higher compared to that of solvent control (p <0.05), it
was termed as significantly agonistic XER/XAR (i.e. sig-
nificantly increased xenoestrogenic/xenoandrogenic
transactivity); 2) the competitive xenohormone transac-
tivity was determined upon co-treatment with 17 b-
estradiol (E2) at EC40-E2 or the synthetic testosterone
R1881 at EC50-R1881 and the serum F1 POP extract
(termed XERcomp/XARcomp) to test primarily for
antagonistic effects on ligand induced receptor transac-
tivity (i.e. response of serum F1 POP extract plus E2 or
R1881 were significantly lower than the response of E2
or R1881 alone), but if the response was significantly
higher than the ligand reference values an additive or
synergistic effect is indicated [51,52]. Measurements of
the serum xeno-estrogen and xeno-androgen receptor
transactivity were conducted at Centre of Arctic Envir-
onmental Medicine & Cellular & Molecular Toxicology,
Department of Public Health, Aarhus University,
Denmark.
Serum extraction of POPs for AhR-transactivity
determination
A semi-automated solid-phase extraction method was
used to prepare purified extracts for AhR-mediated tran-
scriptional activity analyses from a single 5-ml plasma
sample as described in Medehouenou et al. [54]. In
short, the plasma sample was mixed with equal parts of
formic acid and deionised water and extracted using a
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extract was cleaned up on activated silica/acidic silica
column and the compounds were eluted with dichloro-
methane. The solvent was evaporated to dryness and
the resulting fraction reconstituted in 5 μl of dimethyl-
sulfoxide for the measurement of AhR-mediated tran-
scriptional activity [54].
Measurement of AhR-mediated transactivity
Detail procedure of AhR-mediated transactivity mea-
surement was described elsewhere [54,55]. In short, the
bioassay used to measure the AhR mediated transactiv-
ity was based on the expression of the firefly luciferase
in H4IIE.Luc cells resulting from the activation of the
AhR pathway by AhR activating compounds. H4IIE.Luc
cells (kindly donated by A. Brouwer, BioDetection Sys-
tems B.V., Amsterdam, The Netherlands) were obtained
by transfecting rat hepatoma H4IIE cells with the luci-
ferase reporter gene plasmid pGudLuc1.1 [56,57]. After
H4IIE.Luc cells were exposed to TCDD standards and
the cleaned plasma extracts for 24 h, the luciferase
activity was measured. AhR-mediated transcriptional
activity of cleaned plasma extracts was interpolated onto
the TCDD dose-response curve of AhR mediated luci-
ferase activity and expressed as TCDD equivalents
(AhR-TEQ), which represents the total TCDD-toxic
potency of a mixture of dioxin-like compounds. The
limit of detection was 30 pg TEQ/L, corresponding to
approximately 5 pg TEQ/g lipids [54]. Measurement of
AhR-mediated transactivity was performed at the Centre
de Toxicologie (CTQ) of the Institut National de Sante
Publique du Quebec (Quebec, Canada).
Statistical analysis
The distribution of data was checked by Q-Q plots. The
natural logarithmic transformed variables improved the
n o r m a l i t ya n dh o m o g e n e i t yo fv a r i a n c ea n dt h u st h e
comparison analysis was performed on the ln-trans-
formed data. Independent student t-test was used to
compare the graphical variables (age, BMI, fatty acids),
chemical variables (PFCs, POPs, metals), xenobiotic
induced transactivities (XER/XERcomp, XAR/XARcomp,
AhR-TEQ) between cases and controls. Comparison of
chemical variables and xenobiotic induced receptor
transctivities was also performed by adjusting for age,
BMI, number of pregnancies and smoking (serum coti-
nine) using ANCOVA analysis. Pearson’s chi-square test
was used to check the difference between cases and con-
trols for frequency of breastfeeding, menopausal status
and agonistic XER/XAR.
Unconditional logistic regression models were used to
estimate the odds ratios (ORs) and 95% confidence
intervals (95% CI) under controlling for potential
confounders. Potential confounders considered for this
analysis included age, BMI, total number of full-term
pregnancies, breastfeeding, menopausal status and
serum cotinine based on a priori consideration of the
research design and well-established breast cancer risk
factors. Each potential confounder was included in the
model one by one with the chemical variables or xeno-
biotic induced receptor transactivities and compared to
the model only with the chemical measurements or
xenobiotic induced receptor transactivities. The con-
founder was identified when the difference of beta coef-
ficients was more than 15%.
All statistical analysis was performed using SPSS ver-
sion 17.0 (SPSS Inc. Chicago, IL, USA) conducted at
Centre of Arctic Environmental Medicine & Cellular &
Molecular Toxicology,, Department of Public Health,
Aarhus University, Denmark. The statistical significant
level was set to p ≤ 0.05.
Results
Demographic, lifestyle and reproductive characteristics of
the study population
Table 1 summarize the demographic, lifestyle and repro-
ductive characteristics of the breast cancer (BC) cases
and controls. Median age of the BC patients and con-
trols was 50 and 54 years, respectively, and no signifi-
cant age difference was observed. The age distributions
at ≤ 55, 56-59 and ≥ 60 of cases and controls were simi-
lar. Cases and controls had similar BMI. The seafood
intake, represented by the ratio of n-3 fatty acid to n-6
fatty acid (n-3/n-6), did not differ between cases and
controls. To evaluate the current smoking status of the
participants, serum cotinine levels of participants were
measured, and borderline lower level was found for BC
cases compared to their controls, indicating less current
smoking among the cases than control participants. For
the smoking behaviour obtained from the questionnaire,
no significant difference between cases and controls was
observed (Table 1).
As shown in Table 1, the BC cases had lower full
pregnancies numbers compared to the controls. How-
ever, this difference might be suggestive since only 52%
of cases and 77% of controls had information on preg-
nancy; the proportion of breast feeding of BC patients
was similar to that of the control participants. Similar
percent of information on menopausal status for cases
and controls (65% and 77%, respectively) was given. A
substantial proportion of breast cancer patients were
premenopausal (55%) while most of controls were post-
menopausal (82%). The serum level of estradiol (E2) was
non-significantly higher in BC cases compared with con-
trols. In both cases and controls the premenopausal
women had higher E2 level (Table 1).
Bonefeld-Jorgensen et al. Environmental Health 2011, 10:88
http://www.ehjournal.net/content/10/1/88
Page 7 of 16Serum levels of POPs, metals and xenobiotic induced
receptor transactivities POPs
The serum level of perfluorinated compounds (PFCs)
was clearly significant higher in BC cases than controls
(Table 2), and this significantd i f f e r e n c ep e r s i s t e du p o n
adjustment for age, BMI, pregnancy and cotinine. For
PFOS and the sum of perfluorsulfonated acids
(sumPFSA), breast cancer patients had double median
level compared to the controls (p < 0.0001, Table 2),
and for PFOA and sum PFCA the significant difference
between cases and controls was given by p = 0.04 and p
= 0.001, respectively. No significant difference was
observed between cases and controls for the legacy
POPs such as PCBs and OCPs (Table 2). However,
when the PCBs were subdivided into quartiles, the high-
est PCBs quartile (PCBs > 2645 ug/kg lipid) was signifi-
cantly higher for the cases compared with the controls
(p = 0.02, Table 2). Also upon pooling the data for
legacy POPs and PFCs, the cases had significantly higher
level than that of controls (p = 0.007, Table 2). Similar
tendency was observed when data was stratified by
menopausal status (see additional file 1).
Metals
Levels of selected trace elements and heavy metals in
the study participants are given in Table 2. The level of
Zn was significantly higher in cases, and a borderline
higher level of Cd was found for controls. Although not
significant the selenium (Se) level in BC cases tended to
be lower than that of controls. But for the heavy metals
Pb and Hg, no significant difference was observed
between cases and controls.
POP related receptor transactivities
The xenobiotic potential of the extracted serum POP
mixture was analyzed for effects on nuclear receptor
transactivities such as ER, AR and AhR ex vivo upon
exposure of the respective cell cultures as shown in
Table 3. Serum xenoestrogenic transactivities (XER,
XERcomp) did not differ significantly between the two
groups, but BC cases elicited a higher subject sample
frequency of significant agonistic xenoestrogenic trans-
activity compared to controls (38.7% vs. 32.7%; Table 3
and Figure 2). The agonistic xenoandrogenic transactiv-
ity (XAR) of cases was significantly higher than that of
Table 2 Serum levels of POPs and blood metals in breast cancer patients and controls
Cases Controls p value
N (n) median 95% CI Min-max N (n) median 95% CI Min-max
POPs
PFOS(ng/ml) 31(31) 45.6 45.7; 69.3 11.6-124 115(98) 21.9 31.1; 46.0 1.5-172 <0.0001
PFOA(ng/ml) 31(31) 2.5 2.2; 3.4 0.2-7.2 115(98) 1.6 2.11; 2.9 0.2-7. 6 0.04
Sum PFSA(ng/ml) 31(31) 48.2 49.6; 74.6 13.2-133 115(98) 24.6 33.7; 49.7 2.0-184 <0.0001
Sum PFCA(ng/ml) 31(31) 8.0 7.9; 11.9 3.3-21.4 115(98) 5.2 6.4; 9.2 1.0-28.1 0.001
Sum PCB(μg/kg lipid) 31(30) 2049 1596; 2870 150.5-6528 115(115) 1867 1759; 2203 92.7-5640 0.69
< 920 (μg/kg lipid) 10 548 386; 734 151-857 23 451 379; 581 92.7-893 0.41
920-1745(μg/kg lipid) 4 1343 806; 1907 1016-1724 31 1314 1263; 1438 1015-1737 0.95
1745-2645(μg/kg lipid) 7 2222 2088; 2499 1995-2585 32 2163 2118; 2315 1753-2623 0.46
> 2645(μg/kg lipid) 9 4248 3637;5231 2923-6528 29 3308 3267; 3903 2709-5640 0.02
Sum OCP (μg/kg lipid) 31(30) 2532 2224; 3581 250-7320 115(115) 2400 2130; 2678 128-8804 0.19
Sum DL-PCB (μg/kg lipid) 31(30) 149 141; 253 17.9-527 115(115) 198 189; 238 8.4-596.0 0.39
Sum PCB + sum OCP (μg/kg lipid) 31(30) 4424 3861; 6410 401-11849 115(115) 4206 3902; 4869 236-13300 0.35
Sum PCB + sum OCP + sum PFSA + sum
PFCA (ng/ml)
31(31) 81.0 83.1; 124 22.1-231.8 115(115) 59.4 66.6; 88.0 4.9-298.0 0.007
Metals
Se (μg/kg) 31(30) 216 195; 439 101-1877 115(115) 265 294; 405 86.6-1805 0.56
Cd (μg/kg) 31(30) 0.9 0.6; 1.1 0.0-2.7 115(111) 1.03 1.11; 1.51 0.0-6.5 0.09
Hg (μg/kg) 31(30) 16.9 14.4; 24.6 1.54-61.7 115(115) 14.6 15.3; 23.8 0.4-194.0 0.30
Pb (μg/kg) 31(30) 42.7 37.1; 60.4 10.8-134 115(115) 53.2 60.6; 86.6 2.1-499.0 0.23
Zn (μg/kg) 31(30) 5643 5360; 6270 3013-8583 115(89) 4879 4754; 5301 2431-10822 0.003
N: total number of subjects, n: number of subjects having information for the corresponding parameters.
CI: confidence interval. SumPFSA: sum of PFOS, PFHxS and PFOSA; sumPFCA: sum of PFHpA, PFOA, PFNA, PFDA, PFUnA, PFDoA and PFTrA; sum PCB: sum of PCB
99, 101,105,118,128,138,153,156,170,180,183,187; sumOCP: sum of p, p’-DDT, p, p’-DDE, b-HCH, aldrin, HCB, oxychlorodane, cis-nonachlor and trans-nonachlor.
SumDL-PCB (dioxin-like PCB): sum of PCB 105, PCB 118, and PCB 156.
Bonefeld-Jorgensen et al. Environmental Health 2011, 10:88
http://www.ehjournal.net/content/10/1/88
Page 8 of 16controls (p = 0.01, Table 3), and the cases also elicited
higher subject frequency of significantly increased ago-
nistic XAR (18.5% vs. 5.2%; Table 3 and Figure 2) com-
pared to the controls. For the XER and XAR data no
differences was found before and upon adjustment for
the confounder’s age, BMI, pregnancy and cotinine.
Moreover, the serum AhR toxic equivalent (AhR-TEQ)
of cases was lower than controls (p = 0.009, Table 3 and
Figure 2); however, upon adjustment for age, BMI, preg-
nancy and cotinine the significance disappeared (data
not shown).
Odd Ratios of correlation of serum POPs, metals and
xenobiotic transactivities with the risk of breast cancer
Both before and after adjustment for the corresponding
confounders, BC risk was associated with serum levels
of PFOS (adjusted OR = 1.03, p = 0.05) and the sum of
perfluorsulfonated acids (sumPFSA) (adjusted OR =
1.03, p = 0.02) (Table 4). Breast cancer risk was not
associated with serum legacy POPs neither before nor
after adjustment for the corresponding confounders
(Table 4). However, the sum of legacy POPs and PFCs
was significantly associated with the risk of BC (adjusted
OR = 1.02, p = 0.01, Table 4).
The blood level of the trace element Se was not asso-
ciated with BC risk (Table 4). None of the heavy metals
were found to associate to the risk of breast cancer
(data not shown). The integrated xenoestrogenic
transactivity (XER) in serum was not associated with the
risk of BC either before or after adjustment for confoun-
ders, whereas the integrated agonistic xenoandrogenic
transactivity (XAR) in serum was significantly associated
with the BC risk (adjusted OR = 44.1, p = 0.016, Table
4) both before and after adjusting for confounders.
However, the AhR-TEQ was not found associated with
the BC risk (Table 4).
Discussion
This study aimed at evaluating the association between
serum levels of legacy POPs and PFCs in Greenlandic
Inuit breast cancer cases and their controls. The present
data shows for the very first time a relation between the
serum level of PFCs and the risk of breast cancer in
Greenlandic Inuit. Moreover, the breast cancer cases
also had a significant higher serum PCB level at the
highest quartile. In addition, the cases elicited a higher
frequency of subjects samples inducing POP related hor-
mone-like agonistic xeno-ER (XER) and xeno-AR (XAR)
transactivity being significantly different for XAR. In
contrast, the serum POP related dioxin-like AhR-TEQ
was lowest in BC cases, although the significance disap-
peared for the adjusted data.
Until now very few reports are published concerning
the incidence of breast cancer in the Arctic population
and to our knowledge none have ever evaluated the fac-
tors affecting the risk of breast cancer in Greenlandic
Table 3 Serum POP related xenobiotic induced receptor transactivities in breast cancer patients and controls
Parameters Cases Controls p value
N (n) median 95% CI Min-max N(n) median 95% CI Min-max
XER (RLU/μg protein) 31(31) 1.07 1.02; 1.10 0.80-1.30 115(110) 1.08 1.05; 1.11 0.54-1.34 0.69
% agonistic XER 38.7% 32.7% 0.54
% downregulated XER 9.7% 8.2% 0.79
XERcomp (RLU/μg protein) 31(31) 1.06 1.00; 1.08 0.79-1.27 115(110) 1.04 1.00; 1.05 0.55-1.26 0.58
% additive XERcomp 22.6% 19.1% 0.67
% antagonistic XERcomp 12.9% 12.7% 0.16
XAR (RLU/μg protein) 31(27) 1.02 0.97; 1.25 0.56-2.01 115(58) 0.91 0.86; 0.99 0.40-1.74 0.01
% agonistic XAR 18.5% 5.17% 0.02
% downregulated XAR 11.1% 24.1% 0.17
XARcomp (RLU/μg protein) 31(27) 0.69 0.61; 0.82 0.14-1.33 115(58) 0.72 0.68; 0.79 0.29-1.23 0.51
% additive XARcomp 3.7% 0.0 0.14
% antagonistic XARcomp 55. 6% 36.2% 0.59
AhR-TEQ (pg/L) 31(29) 292 285; 568 31.41-1442 115(113) 503 771; 1544 112-12757 <0.0001
AhR -TEQ (pg/g lipid) 31(29) 56.8 46.40; 90.80 8.97-231 115(113) 65.4 103; 219 11.50-2086 0.009
N: total number of subjects, n: number of subjects having information for the corresponding parameters.
XER and XAR: ER and AR transactivity of serum POP F1 extract alone, respectively. XERcomp and XARcomp: competitive receptor transactivity upon co-treatment
with E2 or R1881, respectively. % agonistic XER and % XAR indicate a significant increase for the XER and XAR transactivity compared to the activity of the
solvent control. % downregulated XER and % XAR indicated a significant decrease for the XER and XAR transactivity compared to the activity of the solvent
control. % additive XERcomp and % additive XARcomp indicate a significant increase for the XERcomp and XARcomp transactivity compared to the activityo f
the E2-EC40 and R1881-EC50 solvent control, respectively. % antagonistic XERcomp and % antagonistic XARcomp indicate a significant decrease for the XERcomp
and XARcomp transactivity compared to the activity of the E2-EC40 and R1881-EC50 solvent control, respectively. TEQ (TCDD equivalent): The TEQ value was
calculated by interpolation of the AhR transactivity of serum extract to the TCDD dose-response curve using Sigmaplot program.
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Page 9 of 16Inuit. In the western world BC is the most common
cancer for women [1,2], where established risk factors
can explain less than 30% of the cases. The incidence of
BC has traditionally been low among the Inuit, but
since the 1970’s a considerable increase has been
observed [3,4] although still at a level being approxi-
mately 60% of the incidence in e.g. Denmark [58]. In
the Arctic, before 1966 BC was reported absent from
the western and central Canadian Arctic and from 1967
to 1980 only 2 BCs out of 107 cancers were found [59].
Breast cancer was studied over a 20-year period in Inuit
populations in the circumpolar region. A total of 193
BC’s were observed in women with an incidence
increase from 28.2 per 100.000 in 1969-1973 to 34.3 per
100.000 in 1984-1988 [60]. In Greenland, the age
adjusted incidence in women increased from 35 to 46.4/
100000 in the period 1973-87 and 1988-97, respectively
[58]. Among Greenlandic women, an increase is particu-
lar observed among older women e.g. at the age from
40 to 70 the increase was (~65/100,000) in 1973 - 87
compared to (~170/100,000) the period 1988-97. [58,4].
There is a pattern shift typically seen in low-risk coun-
tries with stagnation or falling rates after menopause to
increased rates after menopause as observed in the Wes-
tern countries. This pattern shift does not support a
general improved diagnosis that would be expected to
be reflected across all age groups. Ethnic and interna-
tional differences in BC risk can mostly be explained by
differences in environmental exposures and lifestyle,
particularly reproductive and hormonal factors [6-8].
The increasing prevalence of obesity and type-2 diabetes
[61], and change in breastfeeding from prolonged feed-
ing continuing through childbearing years to a pattern
of breastfeeding now more similar to the western world
[4] could be consisting with the increase in Arctic BC
rates. However, low parity, late age at first birth and
obesity is also risk factors for hormone-related cancers
such as uterine and ovarian cancer that have not elicited
a parallel increase in incidence in the Arctic and thus
other factors may be important for the increase in BC
incidence [4].
In this study the median age and BMI were similar for
BC cases and the controls and no difference in breast-
feeding was found. The only established reproductive BC
risk factor found significantly different from the controls
was, that BC cases had a lower number of full term preg-
nancies, although this information was only obtained for
approximately 50% and 77% of the cases and control par-
ticipants, respectively. In contrast to the expected meno-
pausal related BC risk a higher frequency of cases were
premenopausal (55% vs. 18%), and for the controls a
higher percent of the subjects were postmenopausal. We
found that postmenopausal women had higher burden of
PFCs and legacy POPs than premenopausal women both
in cases and controls, supporting the known age-depen-
dent bioaccumulations of these compounds [25,43]. It is
expected that premenopausal women are at general
lower risk for BC than postmenopausal women. How-
ever, we observed a higher frequency of premenopausal
w o m e ni nt h ec a s eg r o u pd u r i n gt h es a m p l i n gp e r i o d
2000-2003. We suggest that the combined endogenous
and xenobiotic related hormone disruption might be
higher for cases compared to controls as hypothesized in
the following: Premenopausal cases, although relatively
shorter lifetime exposure to endogenous estrogens but
higher actual estrogen levels, the higher legacy POPs and
PFC serum levels contributes to a higher POP related
xenobiotic estrogenic disruptions. For the postmenopau-
sal cases, although lower actual level of endogenous
estrogen, the BC risk is influenced by a longer lifetime
estrogenic exposure and the higher legacy POPs and PFC
Figure 2 Levels of serum POP related xenobiotic induced
transactivities of breast cancer cases and controls. A) serum
xenobiotic agonistic induced ER and AR receptor transactivity; B)
serum xenobiotic induced AhR transactivity (see legend to Table 3).
% agonistic XER and XAR indicate a significant increase for the XER
and XAR transactivity compared to the the solvent control. AhR-TEQ:
AhR-TCDD equivalent. *: significant differences between cases and
controls.
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Page 10 of 16serum level contributes to a higher POP related xenobio-
tic estrogenic disruptions. This is supported by our data
analysis stratifying the menopause status showing that
cases had higher levels of PFCs and legacy POPs than
controls both for the premenopausal women as well as
postmenopausal women. In addition, postmenopausal
women might be at higher risk because of significant
higher xenoandrogenic bioactivity in accordance to the
hypothesis of Adams, J.B. [62].
Result from the questionnaire showed similar propor-
tion of reported current smoking for cases and controls.
However, since questionnaire is subjective, the measure-
ment of serum cotinine is more precise to reflect the
current smoking status. The lower level of serum coti-
nine for cases indicates that the cases smoked less but it
can be a result of their disease although the non signifi-
cant lower level of serum Cd in cases supports different
smoking habits for cases.
Table 4 Odds ratios of breast cancer and 95% confidence intervals associated with PFCs and POPs among breast
cancer patients and controls
Raw
1 Raw
2 Adjusted
3
variables n OR p nO R p nO R p
(controls/
cases)
(95% CI) (controls/
cases)
(95% CI) (controls/
cases)
(95% CI)
POPs
PFOS (ng/ml) 98/31 1.01 (1.003; 1.02) 0.02 69/9 1.01(0.99; 1.03) 0.23 69/9 1.03 (1.001;
1.07)
0.05
PFOA(ng/ml) 98/31 1.07 (0.88; 1.31) 0.50 69/7 0.94 (0.05; 1.38) 0.76 69/7 1.20 (0.77;
1.88)
0.43
sumPFSA(ng/ml) 98/31 1.013
(1.002;1.023)
0.02 69/15 1.01(0.99; 1.02) 0.37 69/15 1.03(1.00; 1.05) 0.02
sumPFCA(ng/ml) 98/31 1.05 (0.99; 1.11) 0.14 69/12 1.01(0.93; 1.10) 0.82 69/12 1.07(0.96; 1.18) 0.23
Sum PCB (μg/kg lipid)* 115/30 1.00(1.00; 1.00) 0.35 115/30 1.00(1.00; 1.00) 0.35 115/30 1.00(1.00; 1.00) 0.35
Sum OCP (μg/kg lipid)* 115/30 1.00(1.00; 1.00) 0.13 115/30 1.00(1.00; 1.00) 0.13 115/30 1.00(1.00; 1.00) 0.13
Sum PCB+sum OCP (μg/kg lipid)
*
115/30 1.00(1.00; 1.00) 0.19 115/30 1.00(1.00; 1.00) 0.19 115/30 1.00(1.00; 1.00) 0.19
Sum PCB + sum OCP + sum
PFSA + sum PFCA(ng/ml)
115/31 1.01(1.001; 1.014) 0.03 85/11 1.01(0.99; 1.02) 0.37 85/11 1.02(1.01; 1.04) 0.01
Metals
Se (μg/kg) 115/30 1.0 (0.998; 1.001) 0.61 96/27 0.99(0.998;
1.001)
0.51 96/27 0.999(0.99;
1.001)
0.47
Xenobiotic induced transactivities
XER(RLU/μg protein) 110/31 0.41(0.02; 7.50) 0.55 81/7 0.90
(0.001;663.8)
0.78 81/7 1.17(0.001;
1936)
0.97
XER < 1 23/8 28.9 (0.00;
301126)
0.48 11/3 9.49
(0.00;8.34e8)
0.81 11/3 0.00 (0.00; ∞) 0.65
XER > 1 87/23 0.09 (0.00; 23.8) 0.40 70/6 0.66(0.00; 9476) 0.93 70/6 1.85 (0.00;
79767)
0.91
XERcomp (RLU/μg protein) 110/31 2.15 (0.09; 53.77) 0.64 81/7 0.53(0.00;
18980)
0.91 81/7 0.22(0.00;
1166)
0.73
XERcomp <1 40/9 0.67 (0.00.00; 436) 0.90 20/1 0 (0.00; ∞) 0.995 20/1 0.00 (0.000; ∞) 0.99
XERcomp >1 70/22 0.60 (0.00; 1142) 0.89 61/6 0.06(0.00;
56092)
0.67 61/6 0.00(0.000;
111.6)
0.12
XAR(RLU/μg protein) 58/27 8.52 (1.55; 46.78) 0.01 49/11 28.5 (1.79;
452.6)
0.02 49/11 44.14(1.99;
975.7)
0.02
XARcomp(RLU/μg protein) 58/27 0.70(0.09; 5.31) 0.73 47/7 4.27 (0.17;
106.7)
0.38 47/7 5.04(0.20;
130.3)
0.33
AhR-TEQ(pg/g lipid) 113/29 0.99(0.99; 1.001) 0.09 83/6 1.003(0.98; 1.02) 0.77 83/6 1.01(0.98;
1.029)
0.58
Raw
1: unadjusted data of full number of samples. Raw
2: unadjusted data for the subset having all the corresponding adjustment variables (age, BMI, pregnancy,
cotinine, breastfeeding, menopausal status), Adjusted
3: fully adjusted data for the corresponding confounders. OR: odds ratio. CI: confidence interval. For sum
PFSA, sum PFCA, sum PCB, sum OCP see legend of Table 2. For XER, XERcomp, XAR, XARcomp and TEQ see legend of Table 3. *: not adjusted since no
confounder was identified.
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Page 11 of 16The Arctic Inuit population have one of the highest
burden of POPs globally, particularly in some districts
in Greenland, and the hormone disrupting potential of
the actual mixture of serum POPs have been reported
[63]. The recent increase in BC incidence might be
explained by the high burden of legacy POPs and
increased exposure to new emerging POPs such as PFCs
together with the recent transition in the Inuit diet from
the traditional marine food to more western food and
lifestyle factors such as smoking and alcohol intake.
The ubiquitous presence of PFAAs globally including
the Arctic regions has been documented [64,25], and
unlike legacy POPs the level of PFAAs in marine mam-
mals from Greenland still show an increasing trend in
the past years [65,66].
In the present study we measured 3 PFSA isomers and
7 PFCA isomers and the most abundant isomers were
PFOS and PFOA, and to a less extend PFHxS. The sta-
tistic data for PFHxS was similar to that of PFOS (data
not shown). Since PFOS and PFOA were the most
abundant we use these two compounds as the represen-
tative isomer of PFSAs and PFCAs. For BC cases we
observed a significant higher serum level of PFCs and
for PCBs in the highest quartile, and the adjusted odds
ratios (ORs) indicated a significant risk for BC in rela-
tion to the level of serum PFOS and sumPFSA and total
sum of legacy POPs plus PFCs.
O u rd a t as h o w st oo u rk n o w l e d g ef o rt h ev e r yf i r s t
time an association between the serum level of PFCs
and the risk of breast cancer. The higher levels of PCBs
in BC cases in the present study are supported by pre-
vious reported data [10-12,14].
In general, there have been reported non consistent
association between serum fluorochemical levels and
adverse health effects in human but elevated bladder
cancer mortality among male workers exposed to PFOS
for a minimum of one year [33]. In rats [38] and mice
[39] studies upon gestational exposures to PFOA signifi-
cant increase in mammary fibroadenomas and Leydig
cell adenomas and significant reduction in mammary
differentiation and gland development in dams and
female offspring were reported, respectively. In addition,
PFOA-exposed female pups showed stunted mammary
gland epithelial branching and growth [39]. However,
the hypothesis that the PPAR-a agonistic potential of
PFOA was involved was not supported since PPAR-a
null mice exhibited normal mammary gland develop-
ment [39]. In contrast, over expression of PPAR-a dur-
ing pregnancy in mice impair normal differentiation of
the mammary gland [33]. Thus far, data suggest that
PPAR-a is the most likely target of PFOA and PFOS
with the former having highest affinity in both human
and mouse isoforms [33]. Further research is needed to
elucidate the role of the PPAR pathway on the
mammary gland. Moreover, comparing animal (rodent)
data with human health risk must always be done with
some caution because the exposure profile and often the
body elimination is very different: in animals the expo-
sure is often with single compounds, higher concentra-
tion but relatively short time, whereas in human the
exposure is lifelong with low doses and complex
mixtures.
We found that the serum level of both PFAAs, PFOS
and PFOA, as well as the legacy POPs were significant
higher in the BC cases compared to the controls but the
adjusted OR only indicated significant BC risk for PFOS
and PFSA and upon pooling all the chemical groups.
However, we found in both cases and controls a high
inter-correlation between serum PFSA and PFCA (r =
0.85-0.96, p <0.05) and between these two PFC groups
and the legacy POPs (r = 0.42-0.55, p <0.05). Taken that
into consideration it cannot be predicted which single
compounds or chemical group that play the main role
in the observed increase in BC risk.
Preliminary data suggest that some PFCs might be
weak xenoestrogens [41]. In adult rats it was found that
PFOA led to a decrease in serum testosterone and
increase in serum estradiol levels [33]. Future studies
are needed to understand the possible roles of PFCs as
endocrine disrupters on sex hormone homoeostasis and
function.
In our study the total combined serum POP related
xenobiotic bio-activities reflects the lipophilic legacy
POPs only and does not include the more hydrophilic
PFCs. In cases we found that the POP related serum
agonistic xenoandrogenic transactivity was significantly
associated with the risk of BC as well as a higher num-
ber of subjects with significant increased serum agonis-
tic xenoestrogenic transactivity.
With reference to the induced XAR a significant asso-
ciation to BC risk was found both before and after
adjustment for related confounders. Using a similar ana-
lytical system the biological effects of the total combined
xenoestrogens have been set in relation to the risk of BC
by N. Olea and his co-workers [67,68]. It is well estab-
lished that exposure to estrogens can increase the risk
of breast cancer mainly attributed via their potential to
increase the receptor induced cell proliferation and
thereby expand possible gene damage and mutations in
e.g. either tumour suppressing genes or proto-oncogenes
causing inactivation or activation of the gene expres-
sions of growth factors that act on mammary epithelial
cells in an autocrine or paracrine loop [69]. Thus the
body burden of exogenous estrogens such as POP
related xenostrogens may further increase the BC risk.
Adams, J.B. [62] proposed a role of adrenal androgens
(AA) in the aetiology of breast cancer. Premenopausal
women that develop BC tend to have subnormal serum
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Page 12 of 16levels of AA and thus lower androgens acting via the AR
opposing the estrogenic stimulated cell growth during
this life period. In contrast, subjects developing the dis-
ease postmenopausal have supranormal levels of AA,
and the elevated AA levels stimulate cell growth by the
action of 5-androsten-3b,1 7 b-diol, termed hermaphro-
diol, via its combination with the ER in a milieu having
low concentrations of the classical E2. It might be
hypothesized that the significantly higher combined
serum POP related xenoAR activity level in cases has
contributed to the BC development predominantly in
the postmenopausal cases whereas the higher frequency
of cases eliciting significant agonistic POP related
xenoestrogenic transactivity might affect the BC risk in
both pre- and postmenopausal cases. However, further
research is needed before any conclusion can be taken.
In the present study we observed a significant lower
level of AhR-TEQ in BC cases compared to their con-
trols although the significance disappeared upon adjust-
ment for the corresponding confounders (age, BMI,
pregnancy, breastfeeding and cotinine). The higher
serum sum POP/sumPCB levels in cases may explain
the observed difference between cases and controls.
Non-dioxin-like PCBs are shown to have the potential
to antagonize the AhR pathway [70,71], supporting our
unpublished in vitro studies (manuscript in preparation).
Moreover, we found in an earlier study that Inuit with
high serum levels of PCB had lower AhR-TEQ com-
pared to Europeans with lower PCB levels [55]. Dioxins
are reported to have antiestrogenic potentials [72-74]. It
can be speculated whether the lower dioxin-like AhR-
TEQ level in cases could play a role in BC risk via its
lower antiestrogenic potential. Alternatively, it may be
explained by differences between cases and controls
regarding metabolic pathways involved in the biotrans-
formation of both mono-ortho PCBs and estrogens as
suggested by Demers et al. 2002 [75].
In spite of the POPs the traditional diet might also
offer some protection against breast cancer because the
marine diet is rich in 22:6, n-3 fatty acids and the anti-
oxidant selenium (Se) [76], both factors suggested to
have inhibitory effect on breast cancer [77,78] and che-
mically induced carcinogenesis in animals [79]. In addi-
tion, the intake of n-3 fatty acids is associated to the
level of Vitamin A and D. An inverse relation between
Zn and breast cancer was reported [80], and solar radia-
tion and thus Vitamin D was suggested to reduce BC
risk [81]. The intake of Zn has decreased since 1976
[48,82]. Thus, by changing to the western-lifestyle food
intake the Greenlandic Inuit have a decreased intake of
food factors, which might be protective against the risk
of BC, including n-3 fatty acids, Zn, Vitamin D and Se.
In this study we found a trend to lower n-3/n-6 fatty
acid ratio and lower Se but significantly higher levels of
serum Zn in BC cases. To evaluate whether these fac-
tors contributed to the development of BC needs further
research. However, a recent physiologically based phar-
macokinetic (PBPK) model accounting for any given
physiologic lifetime history using data on pregnancies,
height, weight, and age, estimated the values of physio-
logic parameters (e.g., organ volume, composition, and
blood flow) throughout a woman’s entire life was devel-
oped. This PBPK model showed the limitations of using
a single sample value obtained around the time of diag-
nosis for lifetime exposure assessment and point out the
need to estimate the past POP exposure during time
windows that are hypothesized to be mechanistically cri-
tical in carcinogenesis [83]. These factors may to some
degree explain the controversial reports on POP expo-
sure and breast cancer risk.
In the present study the metals were measured in the
whole blood which primarily reflects the actual metal
exposure. The limitation in reflecting the body burden
prior to the disease will be further discussed in a manu-
script particularly focusing on the effects of metals on
the risk of breast cancer from the same study population
(manuscript is in preparation).
There are some weaknesses in the presented study.
Firstly, the few subjects involved, 31 cases and 115 con-
trols, gives a poor statistically power. However, the
highly related serum PFC levels with the risk of BC can-
cer did persist in all our effort to make up a better case-
control frequency match. The number of controls in the
West region (especially in Nuuk) was higher than other
regions and may have impact on the final results. There-
fore we also evaluated the data by reducing the number
of Nuuk control subjects by matching the age and BMI
with the cases in Nuuk to obtain similar cases/control
ratio as for the other regions. Similar data was found
between the data presented and upon including the
reduced and matched data of Nuuk controls (not
shown). However, a trend of higher level of organo-
chlorine pesticides (OCPs) and competitive xenoestro-
genic transactivity (XERcomp) for cases was observed
being significant by including the reduced and matched
data of Nuuk controls, whereas the observed significant
difference between cases and controls at the highest
PCB quartile and XAR transactivity disappeared prob-
ably due to reduced statistical power (data not shown).
Conclusions
The presented data show a higher level of PFCs and
legacy POP in BC cases indicating that the level of
serum POPs in particularly PFCs might be risk factors
in the development of breast cancer in Greenlandic
Inuit. Furthermore, our data suggest that the higher
level of legacy POP related xenoestrogenic and xenoan-
drogenic agonistic activities in cases compared to
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Page 13 of 16controls can contribute to the development of BC in
Inuit. Further investigations are needed to document
these study conclusions.
Additional material
Additional file 1: Results after being stratified by menopausal
status. Levels of POPs, metals and POP related xenobiotic induced
receptor transactivities of BC cases and controls within the
premenopausal and postmenopausal women are given.
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